ArticleOpen forum infectious diseases2025
Ethnic Disparities in Extrahepatic Manifestations Among People With HCV Infection: A Population-Based Study in British Columbia.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ethnic disparities in extrahepatic manifestations (EHMs) among individuals with chronic hepatitis C virus (HCV) infection are poorly understood, especially in diverse populations. We aimed to examine ethnic disparities in EHMs among individuals diagnosed with HCV in British Columbia (BC), Canada. Methods: Using linked administrative health data from the BC Hepatitis Testers Cohort (1990-2015), we assessed EHMs incidence and risk by ethnicity (East Asian, South Asian, and Other) across 4 groups: individuals who remained untreated, pre-HCV treatment completion, post-HCV treatment completion, and those who spontaneously cleared HCV. EHMs included chronic kidney diseases (CKDs) and end-stage renal diseases (ESRDs), type 2 diabetes (T2DM), stroke, major adverse cardiac events (MACEs), and neurocognitive disorders. To assess the risk of EHMs by ethnicity, we used multivariable cause-specific proportional hazards models. Results: Among 41 874 individuals, South and East Asians had higher incidence rates of CKD and ESRD, T2DM, stroke, and MACE compared with other ethnicities, particularly among untreated individuals. Adjusted analyses showed that untreated South Asians had significantly higher risk of CKD and ESRD (adjusted hazard ratio [aHR] 1.27, 95% confidence interval [CI] 1.02-2.16) and T2DM (aHR 2.12, 95% CI 1.53-2.94). Following HCV treatment, these disparities largely disappeared except for diabetes. Conclusions: This study highlights the disproportionate burden of EHMs among Asians in BC and underscores the potential of HCV treatment to reduce ethnic disparities. Public health programming is needed to increase linkage to HCV treatment among those who remain untreated. Further research should focus on intra-ethnic differences and mechanisms underlying the impact of HCV treatment on mitigating these disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.